




# Targeting mantle cell lymphoma metabolism and survival through simultaneous blockade of mTOR and nuclear transporter exportin-1


## Supplementary Materials



**Supplementary Figure 1: Cell growth inhibition by KPT-185 and AZD-8055 or MLN0128 combination in MCL cells.** Jeko-1, Z138, JVM2, and MINO cells were treated with indicated concentrations of KPT-185, AZD-8055, or KPT-185+AZD-8055 (combination) (A) and KPT-185, MLN0128, or KPT-185+MLN0128 (combination) (B) for 48 hours. Inhibition of cell growth is shown as percent of untreated control cells determined by the CCK-8 assay. Graphs show the means ± SD of the results of three independent experiments.

**A****B**

**Supplementary Figure 2: Induction of cell growth inhibition and cell cycle arrest by the KPT-185 and 2DG combination in MCL cells.** Jeko-1, Z138, JVM2, and MINO cells were treated with indicated concentrations of KPT-185, 2DG, or KPT-185+2DG (combination) for 72 hours. (A) Inhibition of cell growth is shown as percent of untreated control cells determined by the CCK-8 assay. (B) The DNA content was measured by flow cytometry. Graphs show the means  $\pm$  SD of results of three independent experiments.



**Supplementary Figure 3: The expression of HSF1, S6, AMPK, and TSC2 in MCL cells treated with KPT-185 and/or AZD-2014.** The averaged p-HSF1 levels relative to HSF1; p-S6 levels relative to total S6; and p-AMPK levels relative to AMPK, and p-TSC2 levels relative to TSC2 after background subtraction. Graphs show the means  $\pm$  SEM of the results of three independent experiments.

**Supplementary Table 1: Clinical characteristics of MCL patients**

Patient number	source	age/sex	Cytogenetics (FISH)
1	BM	74/M	IGH/BCL-1 (CCND1) 59.8%
2	PB	63/F	IGH/BCL-1 (CCND1) 34.0%

**Supplementary Table 2: Frequently altered proteins in MCL cells after treatment with KPT-185, AZD-2014, or KPT-185+AZD-2014. See Supplementary\_Table\_2**

**Supplementary Table 3: Frequently altered metabolites in MCL cells after treatment with KPT-185, AZD-2014, or KPT-185+AZD-2014. See Supplementary\_Table\_3**